skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Defects in the HSD11 gene encoding 11[beta]-hydroxysteriod dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency

Journal Article · · Journal of Clinical Endocrinology and Metabolism; (United States)
;  [1];  [2]; ;  [3]; ;  [4]
  1. Cornell Univ. Medical College, New York, NY (United States)
  2. Rainbow Babies and Children's Hospital, Cleveland, OH (United States)
  3. King's College School of Medicine and Dentistry, London (United Kingdom)
  4. Population Council, New York, NY (United States)

The syndrome of apparent mineralocorticoid excess (AME) is a form of low renin hypertension that is thought to be caused by congenital deficiency of 11[beta]-hydroxysteroid dehydrogenase (11HSD) activity. This enzyme converts cortisol to cortisone and apparently prevents cortisol from acting as a ligand for the mineralocorticoid (type I) receptor. It also catalyzes the reverse oxoreductase (cortisone to cortisol) reaction. Four patients with AME and the parents of the first patient described (now deceased) were analyzed for mutations in the cloned HSD11 gene encoding an 11HSD enzyme. A patient with suspected cortisone reductase deficiency was also studied. No gross deletions or rearrangements in the HSD11 gene were apparent on hybridizations of blot of genomic DNA. Direct sequencing of polymerase chain reaction-amplified fragments corresponding to the coding sequences, intronexon junctions, and proximal untranslated regions of this gene revealed no mutations. AME may involve mutations in a gene for another enzyme with 11HSD activity or perhaps another cortisol metabolizing enzyme. 48 refs., 2 figs., 2 tabs.

OSTI ID:
5044107
Journal Information:
Journal of Clinical Endocrinology and Metabolism; (United States), Vol. 77:3; ISSN 0021-972X
Country of Publication:
United States
Language:
English